Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1912 Combined With R-GEMOX Versus R-GEMOX in Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06929624Phase 3Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A1912 in diffuse large B-cell lymphoma (DLBCL), sponsored by Suzhou Suncadia Biopharmaceutical. Started Apr 2025; status: active, not recruiting.
02
Drugs
SHR-A1912
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06929624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929624.